Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485512 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL27200589 | 0.90 | HTR7 (0.62) | HTR7KMT2AMEN1MAPTCASP3 | |
| SCHEMBL5560398 | 0.87 | KMT2A (0.50) | HTR7ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7164306 | 0.87 | GAA (0.55) | HTR7ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL10579985 | 0.84 | HSD17B3 (0.58) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL8995839 | 0.84 | TDP1 (0.52) | ALDH1A1KMT2AMAPTTRPV1NPC1 | |
| SCHEMBL8591084 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1MAPTNPC1 | |
| SCHEMBL8995791 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1MAPTNPC1 | |
| Hydrogen Peroxide SCHEMBL29219018 | 0.81 | LMNA (0.56) | ALDH1A1KMT2AMAPK1CES2CES1 | |
| SCHEMBL266279 | 0.81 | LMNA (0.56) | ALDH1A1KMT2AMAPK1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103694111-B | A kind of preparation method of 4-(4-fluoro benzoyl) butyric acid | ZHEJIANG XINHECHENG CO., LTD. (CN) | 2016-02-03 | — | — | CN | claimed |
| CN-103694111-A | Method for preparing 4-(4-fluorobenzoyl) butyric acid | ZHEJIANG NHU CO LTD | 2014-04-02 | — | — | CN | claimed |
| EP-2004639-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | Teva Pharmaceutical Industries Ltd (IL) | 2008-12-24 | — | — | EP | claimed |
| US-20080032964-A1 | Process for the synthesis of azetidinone | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007120824-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | claimed |
| CN-116981655-A | Haizimabu intermediate and preparation method thereof | 浙江海正药业股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-115583962-A | Isomer of ezetimibe key intermediate and preparation method thereof | 山东新时代药业有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115184485-A | Ezetimibe prodrug impurity detection method | 南京优科生物医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114989123-A | Flavone-3-carboxylic acid compound, bactericidal composition containing compound and application | 长江大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-107488164-A | A kind of Ezetimibe intermediate compound | 山东新时代药业有限公司 | 2017-12-19 | — | — | CN | disclosed |
| CN-107488173-A | A kind of Ezetimibe intermediate and its synthetic method | 山东新时代药业有限公司 | 2017-12-19 | — | — | CN | disclosed |
| US-5145959-A | Enzyme inhibitors; antilipemic agents; treatment of atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5075311-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-24 | — | — | US | disclosed |
| EP-0356788-A2 | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4517301-A | URINALYSIS, METAL SALT OF BETA-KETO ACID/ESTER | MILES LABORATORIES, INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0051209-B1 | DEVICE AND METHOD FOR PREPARATION OF A CONTROL SOLUTION FOR KETONE DETERMINATION | MILES LABORATORIES, INC. (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0029915-B1 | DEVICE AND METHOD FOR THE PREPARATION OF A CONTROL SOLUTION FOR KETONE DETERMINATION AND METHOD OF CALIBRATING A KETONE TEST INSTRUMENT | MILES LABORATORIES, INC. (US) | 1983-07-20 | — | — | EP | disclosed |
| EP-0051209-A1 | Device and method for preparation of a control solution for ketone determination | MILES LABORATORIES, INC. (US) | 1982-05-12 | — | — | EP | disclosed |
| EP-0029915-A1 | Device and method for the preparation of a control solution for ketone determination and method of calibrating a ketone test instrument | MILES LABORATORIES, INC. (US) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032964-A1 | Process for the synthesis of azetidinone | CYP46A1, APOB, CYP51A1 | HTR7 1119/4885ALDH1A1 464/4885KMT2A 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.